BAFF在原发免疫性血小板减少症中的研究进展
Research Progress of BAFF in Primary Immune Thrombocytopenia
DOI: 10.12677/ACM.2023.13112603, PDF,   
作者: 王 蕾：新疆医科大学第一临床医学院，新疆 乌鲁木齐；郭新红*：新疆医科大学第一附属医院血液三科，新疆 乌鲁木齐
关键词: B细胞激活因子；原发免疫性血小板减少症；研究进展；B Cell Activating Factor； Primary Immune Thrombocytopenia； Research Progress
摘要: 原发免疫性血小板减少症(ITP)是临床上常见的获得性自身免疫性疾病，尽管其发病机制尚未被完全阐明，但多认为B细胞、T细胞所致免疫失调是ITP发病的主要原因。随着研究的深入，一种对B细胞的生存、分化和免疫球蛋白产生起调节作用的细胞因子——B细胞激活因子(B-cell Activating Factor, BAFF)，在系统性红斑狼疮、类风湿性关节炎、干燥综合征等多种自身免疫系统疾病中起着重要的作用，并与原发免疫性血小板减少症的发病密切相关。本文将对BAFF的最新功能研究、在免疫系统等疾病中的作用和机制，以及在ITP领域的最新研究进行全面综述，为进一步的研究和临床治疗提供理论依据。
Abstract: Primary immune thrombocytopenia (ITP) is a common acquired autoimmune disease in clinical practice. Although its pathogenesis has not been fully elucidated, it is widely believed that immune disorders caused by B and T cells are the main causes of ITP. With the deepening of research, a cy-tokine that regulates the survival, differentiation, and immunoglobulin production of B cells, B cell activating factor (BAFF), plays an important role in various autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome, and is closely related to the path-ogenesis of primary immune thrombocytopenia. This article will provide a comprehensive review of the latest functional research, roles and mechanisms of BAFF in diseases such as the immune sys-tem, as well as the latest research in the field of ITP, providing a theoretical basis for further re-search and clinical treatment.
文章引用：王蕾, 郭新红. BAFF在原发免疫性血小板减少症中的研究进展[J]. 临床医学进展, 2023, 13(11): 18522-18526. https://doi.org/10.12677/ACM.2023.13112603

参考文献

[1] Zhang, Y.D., Tian, J. and Xiao, F. (2021) B Cell-Activating Factor and Its Targeted Therapy in Autoimmune Diseases. Cytokine & Growth Factor Reviews, 64, 57-70.
[2] 李会婷, 王丹丹, 熬慧娟, 毕慧. B细胞激活因子在免疫性血小板减少症发病机制中的研究现状[J]. 国际输血及血液病血杂志, 2023, 46(1): 19-25.
[3] Bowman, S.J., Fox, R., Dörner, T., et al. (2022) Safety and Efficacy of Subcutaneous Ianalumab (VAY736) in Patients with Primary Sjögren’s Syndrome: A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Dose-Finding Trial. Lancet, 399, l61-171. [Google Scholar] [CrossRef] 
[4] Wang, Q.T., Ma, Y.K., Huang, B., et al. (2011) Effect of rhTACI-Ig Fusion Protein on Antigen-Specific T Cell Responses from Keyhole Limpet Haemocyanin Challenged Mice. Molecular Immunology, 49, 380-386.
[5] Lai, K.L.Q., King, H.K., Zheng, B.J., et al. (2008) Local BAFF Gene Si-lencing Suppresses Th17-Cell Generation and Ameliorates Autoimmune Arthritis. Proceedings of the National Academy of Sciences of the United States of America, 105, 14993-14998. [Google Scholar] [CrossRef] [PubMed]
[6] Scapini, P., Hu, Y., Chu, C.L., et al. (2010) Myeloid Cells, BAFF, and IFN-γ Establish an Inflammatory Loop That Exacerbates Autoimmunity in Lyn-Deficient Mice. Journal of Experi-mental Medicine, 207, 1757-1773. [Google Scholar] [CrossRef] [PubMed]
[7] Меrrіll, J.Т., Ѕhаnаhаn, W.R., Ѕсhеіnbеrg, M., еt аl. (2018) Рhаѕе Ш Trial Results with Blisibimod, a Selective Inhibitor of B-Cellactivating Factor, in Subjects with Systemic Lupus Erythe-matosus (SLE): Results from a Randomised, Double-Blind, Placebo-Controlled Trial. Annals of the Rheumatic Diseases, 77, 883-889. [Google Scholar] [CrossRef] [PubMed]
[8] Gross, J.A., Johnston, J., Mudri, S., et al. (2000) TACI and BCMA Are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease. Nature, 404, 995-999. [Google Scholar] [CrossRef] [PubMed]
[9] 葛风梅, 王学彬. B细胞激活因子在风湿性疾病中的研究进展[J]. 滨州医学院学报, 2017, 40(1): 62-64, 68.
[10] Thorn, M., Lewis, R.H., Mumbey-Wafula, A., et al. (2010) BAFF Overex-pression Promotes Anti-dsDNA B-Cell Maturation and Antibody Secretion. Cellular Immunology, 261, 9-22. [Google Scholar] [CrossRef] [PubMed]
[11] Dörner, T., Posch, M.G., Li, Y., et al. (2019) Treatment of Primary Sjögren’s Syndrome with Ianalumab (VA Y736) Targeting B-Cells by BAFF Receptor l Blockade Coupled with Enhanced, Antibody-Dependent Cellular Cytotoxicity. Annals of the Rheumatic Diseases, 78, 641-647. [Google Scholar] [CrossRef] [PubMed]
[12] 崔清彦, 颉迎新, 王文欣, 等. 免疫性血小板减少症发病机制的研究进展[J]. 山东医药, 2020, 60(4): 102-105.
[13] 黄炜祺, 周咏明. 原发免疫性血小板减少症的免疫机制研究进展[J]. 中国实验血液学杂志, 2019, 27(4): 339-342.
[14] 文瑞婷, 杨志刚, 聂丽容, 等. B细胞活化因子及调节性T细胞在免疫性血小板减少症发病中的作用[J]. 广东医科大学学报, 2017, 35(4): 353-355.
[15] 隋晓. Th9细胞及IL-9在原发免疫性血小板减少症中的作用研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2020.
[16] 吕俊廷, 梁海燕, 姜朝晖. BAFF在原发免疫性血小板减少症发病中的作用[J]. 临床医学工程, 2018, 25(6): 781-782.
[17] 朱晓璐, 冯非儿, 王谦明, 王辰骢, 张晓辉. B细胞激活因子在免疫性血小板减少性症发病机制中的作用[J]. 中华医学杂志, 2014, 94(48): 3868-3870.
[18] Khalifa, K.A.E., El-Hawy, M.A., Zeid, H.M.A. and El-Kholy, R.M. (2023) Expression of B-Cell Activating Factor in Pediatric Patients with Immune Thrombocytopenia: A Single Institutional Series and Review of Literature. Journal of Immunoassay & Immunochemistry, 44, 41-55. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, Y., Jia, X., Zhou, L., et al. (2021) Increased let-7b-5p Is Associated with Enhanced BAFF-R Expression and B Cell Survival in Immune Thrombocytopenia. International Immunopharmacology, 93, Article ID: 107393. [Google Scholar] [CrossRef] [PubMed]
[20] 张颖, 付妤. B细胞激活因子在慢性炎症性疾病中研究进展[J]. 医学研究杂志, 2021, 50(12): 145-148.
[21] 陈玙, 王梅芳, 陈剑芳, 等. 成人原发免疫性血小板减少症161例疗效及预后的影响因素分析[J]. 中华全科医师杂志, 2018, 17(10): 794-797.

为你推荐